HC Wainwright Comments on CareDx’s Q2 Earnings (NASDAQ:CDNA)

CareDx, Inc (NASDAQ:CDNA) – Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for shares of CareDx in a report released on Monday, May 5th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.09) for the quarter, up from their previous estimate of ($0.15). HC Wainwright currently has a “Neutral” rating and a $25.00 target price on the stock. The consensus estimate for CareDx’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx’s Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.26 EPS.

Other equities analysts have also issued reports about the company. The Goldman Sachs Group decreased their target price on CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Stephens restated an “overweight” rating and set a $40.00 price objective on shares of CareDx in a report on Monday. StockNews.com lowered shares of CareDx from a “buy” rating to a “hold” rating in a report on Monday. Finally, Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and decreased their price target for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.33.

CareDx Stock Up 4.4 %

Shares of CareDx stock opened at $15.42 on Thursday. CareDx has a 12 month low of $9.99 and a 12 month high of $34.84. The business has a fifty day simple moving average of $17.97 and a 200 day simple moving average of $21.21. The stock has a market cap of $858.49 million, a PE ratio of -5.71 and a beta of 2.27.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to analysts’ expectations of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same period last year, the firm earned ($0.03) earnings per share.

Insider Buying and Selling

In other CareDx news, Director Peter Maag sold 13,281 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total value of $228,831.63. Following the sale, the director now owns 316,743 shares in the company, valued at approximately $5,457,481.89. The trade was a 4.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christine Cournoyer sold 16,700 shares of the company’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total value of $235,971.00. Following the transaction, the director now directly owns 37,045 shares of the company’s stock, valued at approximately $523,445.85. This trade represents a 31.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,246 shares of company stock worth $469,498 over the last ninety days. Company insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On CareDx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC grew its holdings in shares of CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock valued at $27,000 after acquiring an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in CareDx by 553.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company’s stock valued at $84,000 after purchasing an additional 3,322 shares during the last quarter. State of Wyoming bought a new position in CareDx in the fourth quarter valued at approximately $91,000. Morse Asset Management Inc acquired a new position in shares of CareDx during the 1st quarter worth approximately $103,000. Finally, Plato Investment Management Ltd raised its stake in shares of CareDx by 34.1% during the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock worth $116,000 after purchasing an additional 1,370 shares in the last quarter.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.